Evoke Pharma Inc

Company Profile

Evoke Pharma Inc had its IPO on 2013-09-25 under the ticker symbol EVOK.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Evoke Pharma Inc has a staff strength of 4 employees.

Stock update

Shares of Evoke Pharma Inc opened at $1.93 at the start of the last trading session i.e. 2023-03-30.

The stocks traded within a range of $1.82 - $1.98, and closed at $1.89.

This is a -5.98% slip from the previous day's closing price.

A total volume of 24,452 shares were traded at the close of the day’s session.

In the last one week, shares of Evoke Pharma Inc have slipped by -28.14%.

Evoke Pharma Inc's Key Ratios

Evoke Pharma Inc has a market cap of $6.72 million, indicating a price to book ratio of 1.0332 and a price to sales ratio of 3.0482.

In the last 12-months Evoke Pharma Inc’s revenue was $2.51 million with a gross profit of $2.14 million and an EBITDA of $0. The EBITDA ratio measures Evoke Pharma Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Evoke Pharma Inc’s operating margin was -310.37% while its return on assets stood at -43.4% with a return of equity of -215.3%.

In Q4, Evoke Pharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 120.9%.

Evoke Pharma Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

-0.1

Its diluted EPS in the last 12-months stands at $-2.12 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.1. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Evoke Pharma Inc’s profitability.

Evoke Pharma Inc stock is trading at a EV to sales ratio of 0.0648 and a EV to EBITDA ratio of 0.1949. Its price to sales ratio in the trailing 12-months stood at 3.0482.

Evoke Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$11.85 million

Total Liabilities

$1.65 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Evoke Pharma Inc ended 2023 with $11.85 million in total assets and $0 in total liabilities. Its intangible assets were valued at $11.85 million while shareholder equity stood at $4.08 million.

Evoke Pharma Inc ended 2023 with $0 in deferred long-term liabilities, $1.65 million in other current liabilities, 334.00 in common stock, $-115647143.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.84 million and cash and short-term investments were $9.84 million. The company’s total short-term debt was $129,074 while long-term debt stood at $0.

Evoke Pharma Inc’s total current assets stands at $11.72 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $624832.00 compared to accounts payable of $934312.00 and inventory worth $289378.00.

In 2023, Evoke Pharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Evoke Pharma Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$1.89

52-Week High

$10.536

52-Week Low

$1.372

Analyst Target Price

$7

Evoke Pharma Inc stock is currently trading at $1.89 per share. It touched a 52-week high of $10.536 and a 52-week low of $10.536. Analysts tracking the stock have a 12-month average target price of $7.

Its 50-day moving average was $3.35 and 200-day moving average was $2.64 The short ratio stood at 2.39 indicating a short percent outstanding of 0%.

Around 246.4% of the company’s stock are held by insiders while 182% are held by institutions.